Abstract
Introduction
Treatment of skin and skin structure infections often requires systemic
antibacterial therapy. Two trends are concerning physicians: the spread of
methicillin-resistant Staphylococcus aureus (MRSA), particularly
community-acquired strains (CA-MRSA) have become the most important pathogen
in the US; and a slow but measurably declining susceptibility to vancomycin by
these bacteria.
Scope of this research
- Epidemiological trends and economic impact of key pathogens
- Overview of diagnosis and referral patterns
- Analysis of present and future unmet needs with outline of key drugs in
development for SSTIs
- Outline of drivers of treatment choice in both the hospital and the
community setting
Research and analysis highlights
Guideline adoption for skin and soft tissue infections (SSTIs) among
specialists is fairly strong, but less so among primary care physicians
(PCPs). PCPs treat mild-to-moderate forms of disease, representing an
estimated 70% of SSTI patients, while specialists treat severe SSTI sufferers
(30%).
Resistance is the single most important factor affecting the SSTI drug market,
in both the community and hospital settings. Vancomycin has traditionally been
viewed as the most effective treatment option for SSTIs caused by MRSA,
although bacterial resistance to the drug is emerging and it is becoming less
effective for the treatment of SSTIs.
A highly valuable new SSTI drug should possess a number of important
characteristics, including strong bactericidal activity against MRSA, VISA,
and H-VISA strains, a good toxicity and side effect profile,
cost-effectiveness, good tissue penetration for systemic use, superior
efficacy versus vancomycin, and broad spectrum coverage.
Key reasons to purchase this research
- Identify key opportunities that will impact the use and uptake of new and
existing products
- Understand the critical issues that drive prescription choice in skin and
soft tissue infections
- Learn about the difference between key antibacterial drug attributes
relevant to hospital and community-based physicians
| 
View Cart
